Cargando…

Obesity – should we revise indications for treatment with metformin?

INTRODUCTION: Treatment of obesity with life style modifications often fails; therefore pharmacological treatment has become a very popular approach. Metformin is one of the examined possibilities. The aim of this study was to verify indications for metformin use in obese women based on metabolic an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kujawska-Luczak, Magdalena, Stankowiak-Kulpa, Hanna, Swora-Cwynar, Ewelina, Musialik, Katarzyna, Bogdański, Paweł, Suliburska, Joanna, Grzymisławski, Marian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520349/
https://www.ncbi.nlm.nih.gov/pubmed/26327840
http://dx.doi.org/10.5114/pm.2014.42713
_version_ 1782383648672055296
author Kujawska-Luczak, Magdalena
Stankowiak-Kulpa, Hanna
Swora-Cwynar, Ewelina
Musialik, Katarzyna
Bogdański, Paweł
Suliburska, Joanna
Grzymisławski, Marian
author_facet Kujawska-Luczak, Magdalena
Stankowiak-Kulpa, Hanna
Swora-Cwynar, Ewelina
Musialik, Katarzyna
Bogdański, Paweł
Suliburska, Joanna
Grzymisławski, Marian
author_sort Kujawska-Luczak, Magdalena
collection PubMed
description INTRODUCTION: Treatment of obesity with life style modifications often fails; therefore pharmacological treatment has become a very popular approach. Metformin is one of the examined possibilities. The aim of this study was to verify indications for metformin use in obese women based on metabolic and anthropometric parameters assessed by dual-X-ray absorptiometry (DXA), to establish the degree of insulin resistance and its correlations. MATERIAL AND METHODS: Anthropometry, fat measurement by bioimpedance and metabolic profile, including lipids, and oral glucose tolerance test (OGTT) with insulin (0 and 120 min) were performed in 50 female patients diagnosed with simple obesity, aged 18-40 years. Homeostatic model assessment HOMA-R was calculated for insulin resistance, and area under the curve (AUC) for insulin response. Total, android and gynoid fat distribution, and their ratio (A/G), were measured by DXA. RESULTS: From 50 women who entered the study, 33 were classified as insulin resistant (IR subgroup) and 17 as non-insulin resistant (non-IR subgroup), according to their HOMA-R indices. IR women presented higher waist circumference and DXA A/G ratio. The IR subgroup demonstrated elevated fasting triglycerides and glucose (but in the normal range) and a higher insulin response in OGTT (4.1-fold vs 2.5-fold). From different insulin measurements HOMA index turned out to have the strongest correlations with the metabolic parameters triglycerides and glucose. We found significant positive correlations between android fat and insulin: waist circumference and HOMA-R, WHR and HOMA-R, android fat and HOMA-R, A/G ratio and insulin after OGTT, and A/G ratio and HOMA-R. We found a strong correlation between WHR and A/R ratio. CONCLUSIONS: 67% of premenopausal obese women were insulin resistant. Measures of DXA visceral fat determined by android fat percentage and android/gynoid ratio were the strongest determinants of insulin resistance. Waist-to-hip ratio might be a simple method for determining the indications for metformin treatment.
format Online
Article
Text
id pubmed-4520349
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-45203492015-08-31 Obesity – should we revise indications for treatment with metformin? Kujawska-Luczak, Magdalena Stankowiak-Kulpa, Hanna Swora-Cwynar, Ewelina Musialik, Katarzyna Bogdański, Paweł Suliburska, Joanna Grzymisławski, Marian Prz Menopauzalny Original Paper INTRODUCTION: Treatment of obesity with life style modifications often fails; therefore pharmacological treatment has become a very popular approach. Metformin is one of the examined possibilities. The aim of this study was to verify indications for metformin use in obese women based on metabolic and anthropometric parameters assessed by dual-X-ray absorptiometry (DXA), to establish the degree of insulin resistance and its correlations. MATERIAL AND METHODS: Anthropometry, fat measurement by bioimpedance and metabolic profile, including lipids, and oral glucose tolerance test (OGTT) with insulin (0 and 120 min) were performed in 50 female patients diagnosed with simple obesity, aged 18-40 years. Homeostatic model assessment HOMA-R was calculated for insulin resistance, and area under the curve (AUC) for insulin response. Total, android and gynoid fat distribution, and their ratio (A/G), were measured by DXA. RESULTS: From 50 women who entered the study, 33 were classified as insulin resistant (IR subgroup) and 17 as non-insulin resistant (non-IR subgroup), according to their HOMA-R indices. IR women presented higher waist circumference and DXA A/G ratio. The IR subgroup demonstrated elevated fasting triglycerides and glucose (but in the normal range) and a higher insulin response in OGTT (4.1-fold vs 2.5-fold). From different insulin measurements HOMA index turned out to have the strongest correlations with the metabolic parameters triglycerides and glucose. We found significant positive correlations between android fat and insulin: waist circumference and HOMA-R, WHR and HOMA-R, android fat and HOMA-R, A/G ratio and insulin after OGTT, and A/G ratio and HOMA-R. We found a strong correlation between WHR and A/R ratio. CONCLUSIONS: 67% of premenopausal obese women were insulin resistant. Measures of DXA visceral fat determined by android fat percentage and android/gynoid ratio were the strongest determinants of insulin resistance. Waist-to-hip ratio might be a simple method for determining the indications for metformin treatment. Termedia Publishing House 2014-05-21 2014-05 /pmc/articles/PMC4520349/ /pubmed/26327840 http://dx.doi.org/10.5114/pm.2014.42713 Text en Copyright © 2014 Termedia http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Paper
Kujawska-Luczak, Magdalena
Stankowiak-Kulpa, Hanna
Swora-Cwynar, Ewelina
Musialik, Katarzyna
Bogdański, Paweł
Suliburska, Joanna
Grzymisławski, Marian
Obesity – should we revise indications for treatment with metformin?
title Obesity – should we revise indications for treatment with metformin?
title_full Obesity – should we revise indications for treatment with metformin?
title_fullStr Obesity – should we revise indications for treatment with metformin?
title_full_unstemmed Obesity – should we revise indications for treatment with metformin?
title_short Obesity – should we revise indications for treatment with metformin?
title_sort obesity – should we revise indications for treatment with metformin?
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520349/
https://www.ncbi.nlm.nih.gov/pubmed/26327840
http://dx.doi.org/10.5114/pm.2014.42713
work_keys_str_mv AT kujawskaluczakmagdalena obesityshouldwereviseindicationsfortreatmentwithmetformin
AT stankowiakkulpahanna obesityshouldwereviseindicationsfortreatmentwithmetformin
AT sworacwynarewelina obesityshouldwereviseindicationsfortreatmentwithmetformin
AT musialikkatarzyna obesityshouldwereviseindicationsfortreatmentwithmetformin
AT bogdanskipaweł obesityshouldwereviseindicationsfortreatmentwithmetformin
AT suliburskajoanna obesityshouldwereviseindicationsfortreatmentwithmetformin
AT grzymisławskimarian obesityshouldwereviseindicationsfortreatmentwithmetformin